Moderator:

***Anil Goyal**, Ph.D., OpenDoors Group*

Dr. Goyal is founder and managing director of consulting firm OpenDoors Group. During the last 20 years, he's been part of the leadership teams at 3 public and 3 private biotechnology companies that were primarily oncology focused. He is currently fractional VP of Business Development at MimiVax, LLC, (an immuno-oncology company with Phase II program for glioblastoma) and Esanex Inc., (with an oral Hsp90 inhibitor entering Phase II for lung cancer). Prior to these companies, he served as VP of Business Development at Heat Biologics (HTBX) immuno-oncology company. From 2010-13 he served as CEO and co-founder of Qualiber, Inc., a cancer nanomedicine company launched from UNC-CH. Other companies during his career included: Ascletis Pharmaceuticals (Hangzhou), Optherion, Serenex (Acquired by Pfizer), Millennium Pharma (Acq. by Takeda), Osient Pharma, and Merck & Co.

Dr. Goyal received his Ph.D. in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey, and is a Certified Licensing Professional (CLP™) by the Licensing Executives Society, Inc.

Panelists:

***Julie Allickson**, Ph.D., Director, Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine*

More than 27 years of experience in clinical translation of cellular therapies and regenerative medicine products including entrepreneurial and business management and board directorship experience. Dr. Allickson has 8 years' experience as an executive officer with a publicly traded company building services for cellular banking including global licensure of technology. An experienced scientist delivering innovation, driving milestones, maintain sensitivity to financial considerations, building high performance multidisciplinary teams, strategic planning, project management, and regulatory expertise. She has lead research & development of tissue/cellular products for service enhancement or commercialization and has extensive experience in tissue/cellular procurement, processing, tissue engineering, cryopreservation, cellular selection/separation, expansion, tissue/cell culture, quality systems compliance, internal/external inspections and transferring technology.
Dr. Allickson heads the clinical translation team streamlining development to create a pipeline of products in early phase clinical trials and FDA registered products including cell therapy, tissue engineered organs and tissues, biomaterials and devices. Prior

to the Institute she was the Vice President of Research and Development and Laboratory Operations for Cryo-Cell International. Dr. Allickson was part of the team to perform the first Bone Marrow Transplant at the University of Miami in 1990. She has a Doctorate in Health Sciences along with a Master's Degree in Medical Laboratory Sciences. She is one of the founding members of the International Society of Cellular Therapy in 1992 and has been a member of the AABB for 27 years and is a member of the Board of Directors for AABB. She is also a member of the scientific advisory board for the Regenerative Medicine Outcomes and an advisory board member for I'm Curable Foundation.



***Tim Bertram**, Ph.D., Chief Executive Officer, inRegen*

Tim has over 30 years of medicine development expertise and led innovations in cellular therapeutics for the past 15 years. He is the CEO of a multi-national privately owned cellular therapeutics company, inRegen, focusing on clinical development of a cell-based medicine targeting the treatment of chronic renal disease. Tim previously served as CEO of RegenMed Therapeutics, after serving as President of Research and Development to bring four cell-based therapeutic products from discovery through Phase II clinical development.

Tim is currently on the board-of-directors for two biotechnology companies developing cellular therapeutic agents. He has also served as a senior scientific executive at Pfizer, SmithKline Beecham Pharmaceuticals, and Procter & Gamble Co; as a faculty member at the University of Illinois; and as a visiting scientist to the National Institutes of Health.

Tim has been a counsel/mentor to scientists in government, academics, and industry. His experience includes worldwide leadership of multidisciplinary scientific teams for the pharmaceutical industry, government and private foundations focusing on the resolution of challenges in pharmaceutical productivity and defining industrial applications of advanced molecular and cellular technologies.

Tim has defined his industrial career as selecting optimal therapeutic candidates for commercial development through the use of his experience in discovery, development and registration of small molecules and cell-based therapy products.

***Peter Johnson**, M.D., Principal, MedSurgPI, LLC*

Peter C. Johnson, MD is a University of Notre Dame and SUNY Upstate Medical University graduate. After General and Plastic Surgery training, Dr. Johnson practiced reconstructive surgery for ten years at U. Pittsburgh where he founded and was the first President of the Pittsburgh Tissue Engineering Initiative. Subsequent roles were co-founder/CEO of Tissue Informatics, EVP of Life Sciences, CMO and CBO of Icoria, EVP, Entegrion, Inc. and VP, Research and Development and Medical and Scientific Affairs of Vancive Medical Technologies, an Avery Dennison business. He presently serves as President and CEO of Scintellix, LLC, Chief Medical Advisor to Vancive Medical Technologies and Co-Founding Principal of MedSurgPI, LLC. He has Chaired the Plastic Surgery Research Council, was President of the Pennsylvania Biotechnology Association and the Tissue Engineering Society, International (now TERMIS) and is presently the Co-Editor-in-Chief of the three-part Journal, Tissue Engineering. He serves on the board of the Transverse Myelitis Association, MEDIC – the Medical Innovators Collaborative, the Industry Advisory Board of the UNC/NC State Joint Program in Bioengineering the Industrial Technology Advisory Board of the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center and is Chairman of the Advisory Board for SonoVol. He is an Adjunct Professor of Biomedical Engineering at the University of North Carolina at Chapel Hill, of Biomedical Engineering at NC State and of Regenerative Medicine at Wake Forest University School of Medicine. He is an avid cook; fly fisherman, artist, novelist and farmer.

***Jeffrey Lawson**, M.D., Ph.D. – Chief Medical Officer, Humacyte*

Dr. Lawson received his Medical Degree, a PhD in Cell and Molecular Biology and completed a Postdoctoral Fellowship in Biochemistry from the University of Vermont. He then completed a residency in General and Thoracic Surgery and a Fellowship in Vascular Surgery at Duke University Medical Center. He is currently Professor of Surgery and Pathology at Duke University and Chief Medical Officer of Humacyte. Dr. Lawson is a physician-scientist, clinically practicing vascular surgery and actively pursuing basic, translational and clinical research. He has had a lifelong interest in the field of blood coagulation and vascular biology and has continuously studied these areas both scientifically and clinically in his laboratory. Dr. Lawson has become a recognized leader in the field of vascular translational technology and his laboratory has successfully developed a number of molecular, cellular and tissue engineered technologies through translational research studies and first-in-man clinical trials. He is the co-author of over 120 journal articles on the topics of hemostasis, tissue engineering and vascular surgery and lectures nationally and internationally on these topics. Dr. Lawson's research laboratory has been funded by grants from the American Heart Association, National Institutes of Health, Department of Defense and various biotechnology companies.